Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer

NCT ID: NCT05850663

Last Updated: 2025-07-03

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-30
• Study Completion Date: 2025-06-04

Brief Summary

The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.

Detailed Description

This study will involve patients who have been diagnosed with head and neck or gynecologic cancers and are receiving radiation treatments via the QUAD shot regimen. It is a single arm pilot trial designed to provide information on the ease of use, feasibility, and perceived usefulness of a smartphone application to monitor symptoms and quality of life during cancer treatment, as well as assess barriers to care and perceptions of the smartphone app.

Patients will download the study app onto their personal smartphone, if the phone is compatible with the app, or a study smartphone will be loaned to them. The smartphone app will first ask patients to complete the 15-25 minute baseline survey, followed by one daily brief survey that ask about symptoms, quality of life, and barriers for 75 days. At the end of this period, the smartphone app will prompt the patient to complete a final survey, followed by a brief in-person or telephone interview to assess opinions about the app. Patients' symptoms, treatment effects, medication adherence, pain, quality of life, and general barriers to care will be assessed with questionnaires to measure the impacts of the mobile health-based assessment platform. Results from this study will be for research only and will not impact treatment decisions.

Conditions

Head and Neck Cancer; Gynecologic Cancer; Cervical Cancer; Endometrial Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Ecological Momentary Assessments (EMAs)

Patients will receive one EMA (Ecologic Momentary Assessment) per day for approximately 75 days, through the provided smart phone application.

Group Type: OTHER

Ecologic Momentary Assessment (EMA)

Intervention Type: OTHER

EMA enables measurement of phenomena in real-time, natural settings.

EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.

The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.

The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone.

Interventions

Ecologic Momentary Assessment (EMA)

EMA enables measurement of phenomena in real-time, natural settings.

EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.

The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.

The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age 18 years and older
• Written informed consent and any locally-required authorization obtained from the patients prior to performing any protocol-related procedures, including screening evaluations
• Pathologically (histologically or cytologically) proven diagnosis of cancer of the head and neck (nasopharynx, oral cavity, oropharynx, hypopharynx, larynx, or unknown primary) or Gynecologic cancers (cervical and endometrial)
• Locally recurrent or metastatic HNC or Gyn cancer not deemed amenable to curative-intent salvage therapy, in whom at least six months have passed since their prior RT, if received
• Must have evaluable lesion per RECIST v1.1
• Patients agree to provide their smoking history prior to registration
• ECOG performance status of 0-2

Exclusion Criteria

• Prior radiotherapy to the region of the study cancer within less than 6 months
• Patients who have received prior radiation therapy and who, in the opinion of the treating radiation oncologist, cannot be reirradiated safely without excess risk of severe toxicity given prior radiation dose to critical structures.
• Patients with known contraindications to radiotherapy, including inherited syndromes associated with hypersensitivity to ionizing radiation (e.g., Ataxia-Telangiectasia, Nijmegen Breakage Syndrome)
• Female patients who are pregnant

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Oklahoma

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

Quadshot mHealth

Identifier Type: -

Identifier Source: org_study_id